Effect of platelet-activating factor on lipoprotein lipase and blood lipids.
We investigated the effect of platelet-activating factor (PAF) and of the PAF specific antagonist CV-6209 on plasma lipid metabolism, and particularly on post-heparin plasma lipolytic activity in male Wistar rats. Lipoprotein lipase (LPL) activity was enhanced by intravenous injection of PAF before intravenous injection of heparin when the PAF dose was low (0.2 micrograms/kg). PAF activated hepatic triacylglycerol lipase (HTGL) activity dose-dependently. Plasma triacylglycerols (TG) significantly decreased with the activation of LPL and/or HTGL. Plasma total cholesterol (TC) and phospholipid (PL) levels decreased at a low dose of PAF (0.2 micrograms/kg), but increased when higher doses were used. The PAF antagonist CV-6209 partially reversed the PAF induced effects on HTGL, TC and PL.
Mimura
K
K
Third Department of Internal Medicine, Wakayama Medical University, Japan.
Yukawa
S
S
Mori
Y
Y
Okada
K
K
Mune
M
M
Nishikawa
O
O
Hibino
A
A
Sonobe
M
M
Goto
T
T
Nomoto
H
H
D000818:Animals; D002784:Cholesterol / Q000097:blood; D007700:Kinetics; D008049:Lipase / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008066:Lipolysis / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000097:blood*; D008297:Male; D010743:Phospholipids / Q000097:blood; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011726:Pyridinium Compounds / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D014280:Triglycerides / Q000097:blood
D008055:Lipids; D010743:Phospholipids; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; D014280:Triglycerides; C053321:CV 6209; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase